Genprex (GNPX) News Today $0.31 +0.02 (+5.45%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.29 -0.02 (-5.78%) As of 05:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Genprex to Participate at BIO 2025 International ConventionJune 3, 2025 | prnewswire.comGenprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingMay 29, 2025 | prnewswire.comGenprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingMay 28, 2025 | prnewswire.comGenprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 DiabetesMay 7, 2025 | prnewswire.comGenprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of GlioblastomaMay 6, 2025 | prnewswire.comGenprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual MeetingApril 30, 2025 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual MeetingApril 29, 2025 | prnewswire.comGenprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of MesotheliomaApril 28, 2025 | prnewswire.comGenprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual MeetingApril 24, 2025 | prnewswire.comGenprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement ProceedingsApril 22, 2025 | prnewswire.comGenprex reports progress in lung cancer gene therapyMarch 29, 2025 | uk.investing.comGenprex to present results preclinical data from Reqorsa studyMarch 27, 2025 | markets.businessinsider.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual MeetingMarch 26, 2025 | prnewswire.comGenprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific SessionsMarch 25, 2025 | prnewswire.comCS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!March 18, 2025 | theglobeandmail.comGenprex to Participate at BIO Europe Spring 2025March 4, 2025 | prnewswire.comGenprex announces advancement of diabetes program, strategic collaborationFebruary 19, 2025 | markets.businessinsider.comGenprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery SystemFebruary 19, 2025 | prnewswire.comGenprex announces advancement of its diabetes gene therapy programFebruary 18, 2025 | markets.businessinsider.comGenprex Provides Update on Diabetes Gene Therapy ProgramFebruary 18, 2025 | prnewswire.comGenprex’s Oncoprex included in lung cancer therapyFebruary 13, 2025 | markets.businessinsider.comGenprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung CancerFebruary 13, 2025 | prnewswire.comGenprex faces Nasdaq delisting over stock price, equity issuesFebruary 12, 2025 | msn.comGenprex doses first subject in expansion part of lung cancer gene therapy trialJanuary 24, 2025 | msn.comGenprex announces first patient dosed with Regorsa in Phase 2 lung cancer studyJanuary 24, 2025 | markets.businessinsider.comGenprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung CancerJanuary 23, 2025 | prnewswire.comGenprex to Participate at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | prnewswire.comGenprex receives Safety Review Committee approval to advance Acclaim-3 trialDecember 17, 2024 | markets.businessinsider.comGenprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerDecember 16, 2024 | prnewswire.comGenprex signs exclusive license agreement with University of MichiganNovember 20, 2024 | markets.businessinsider.comGenprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung CancerNovember 20, 2024 | prnewswire.comGenprex to present positive preclinical data from Reqorsa Gene Therapy studyNovember 6, 2024 | markets.businessinsider.comGenprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingNovember 5, 2024 | prnewswire.comGenprex to Participate in 2024 BIO Europe ConferenceOctober 31, 2024 | prnewswire.comLooking Into Genprex's Recent Short InterestOctober 30, 2024 | benzinga.comGenprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and GlioblastomaOctober 28, 2024 | prnewswire.comGenprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK PositiveOctober 24, 2024 | prnewswire.comGenprex (NASDAQ:GNPX) Stock Quotes, Forecast and News SummaryOctober 22, 2024 | benzinga.comGenprex advances dose in lung cancer trialOctober 17, 2024 | investing.comGenprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung CancerOctober 15, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 10, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual MeetingOctober 7, 2024 | prnewswire.comGenprex, Inc. (GNPX) interactive stock chart – Yahoo FinanceSeptember 25, 2024 | au.finance.yahoo.comGenprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and DiabetesSeptember 23, 2024 | prnewswire.comGenprex Announces Formation of Mesothelioma Clinical Advisory BoardSeptember 19, 2024 | prnewswire.comGenprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsSeptember 9, 2024 | prnewswire.comGenprex Plans To Launch New Subsidiary To Focus Gene Therapy To Treat Type-1, Type-2 DiabetesSeptember 4, 2024 | markets.businessinsider.comGenprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 DiabetesSeptember 4, 2024 | prnewswire.comGenprex to Present and Participate at Upcoming September Investor and Industry ConferencesSeptember 3, 2024 | prnewswire.comGenprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical TrialsAugust 15, 2024 | prnewswire.com Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address GNPX Media Mentions By Week GNPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GNPX News Sentiment▼0.430.90▲Average Medical News Sentiment GNPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GNPX Articles This Week▼21▲GNPX Articles Average Week Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PLUR News Today SCYX News Today RANI News Today TPST News Today KZR News Today FGEN News Today GRCE News Today ALXO News Today PULM News Today COEP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GNPX) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GNPX Stock Free GNPX Stock Alerts